NCT06670105View on ClinicalTrials.gov

A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell Lymphoma

PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

June 6, 2025

Primary Completion Date

January 6, 2030

Study Completion Date

January 6, 2032

Conditions

B-cell Lymphoma

Interventions

DRUG

Glofitamab

Given by vein

Trial Locations (1)

77030

The University of Texas M. D. Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER